$128.29
3.22% yesterday
Nasdaq, Nov 15, 09:46 pm CET
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Ascendis Pharma A/S Sponsored ADR Stock price

$126.51
-0.79 0.62% 1M
+2.47 1.99% 6M
+0.56 0.44% YTD
+33.54 36.08% 1Y
-26.63 17.39% 3Y
+14.00 12.44% 5Y
+107.68 571.85% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+2.23 1.79%
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Key metrics

Market capitalization $7.26b
Enterprise Value $7.70b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.43
P/S ratio (TTM) P/S ratio 21.14
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 171.57%
Revenue (TTM) Revenue $343.17m
EBIT (operating result TTM) EBIT $-382.38m
Free Cash Flow (TTM) Free Cash Flow $-354.18m
Cash position $277.26m
EPS (TTM) EPS $-9.34
P/E forward negative
P/S forward 21.82
EV/Sales forward 23.18
Short interest 8.03%
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
93%
Hold
7%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
343 343
172% 172%
100%
- Direct Costs 66 66
64% 64%
19%
277 277
222% 222%
81%
- Selling and Administrative Expenses 258 258
11% 11%
75%
- Research and Development Expense 382 382
13% 13%
111%
-362 -362
38% 38%
-106%
- Depreciation and Amortization 20 20
5% 5%
6%
EBIT (Operating Income) EBIT -382 -382
37% 37%
-111%
Net Profit -530 -530
16% 16%
-154%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Neutral
Seeking Alpha
about 22 hours ago
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Executive Vice President & Chief Financial Officer Camilla Harder Hartvig - Head of Global Commercial Operation Joe Kelly - US General Manager Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of Ame...
Neutral
GlobeNewsWire
one day ago
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3
Neutral
GlobeNewsWire
about 2 months ago
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency...
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Founded 2006
Website www.ascendispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today